Prices delayed by at least 15 minutes | Print


Skinbiotherapeutics PLC (SBTX)

ORD 1P
Sell: 12.5p|Buy: 13p|Change: 0.38 (3.09%)

Open 

12.25p


Previous close 

12.125p


Trade high 

13.61875p


Volume 

628,676


Year high 

29.50p


Year low 

7.00p


Dividend yield 

-


Market capitalisation 

£24.10 mn


P/E ratio 

-


ISIN 

GB00BF33H870


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Skinbiotherapeutics PLC+ 11.75
FTSE AIM All Share+ 0.35
More...

Company profile

SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202409:53:2512.52,695336.88
28/03/202409:49:2012.8441,245159.91
28/03/202409:46:4212.92595,24112,309.90
28/03/202409:33:2212.510,0001,250.00
28/03/202409:33:2012.527,4213,427.63

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.